Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

2015920 citationsJournal Articlebronze Open Access

Authors

Steven P. Treon · Harvard University

Christina Tripsas · Dana-Farber Cancer Institute

Kirsten Meid · Dana-Farber Cancer Institute

Diane Warren · Dana-Farber Cancer Institute

Gaurav Varma · Stanford Medicine

Rebecca Green · Memorial Sloan Kettering Cancer Center

Kimon V. Argyropoulos

Abstract

Ibrutinib was highly active, associated with durable responses, and safe in pretreated patients with Waldenström's macroglobulinemia. MYD88 and CXCR4 mutation status affected responses to this drug. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01614821.).

Topics & Keywords

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Chronic Myeloid Leukemia Treatments

Publication Details

Published in: New England Journal of Medicine

Volume 372, Issue 15, pp. 1430-1440

DOI: 10.1056/nejmoa1501548

Field-Weighted Citation Impact: 60.76

Command Palette

Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

Authors

Abstract

Topics & Keywords

Publication Details